智通财经APP讯，药明康德(02359)发布公告，该公司于2025年8月13日斥资2799.04万元人民币回购29.2 万股A股，每股回购价格为91.91-98.83元人民币。 ...

Market Overview - A-shares experienced a significant rally, with the Shanghai Composite Index achieving an 8-day winning streak and reaching a new high since December 2021, closing at 3683.46 points, up 0.48% [1] - The total trading volume in the A-share market exceeded 2 trillion yuan for the first time since February 27, with a total of 21,756 billion yuan traded [1] - The Hong Kong stock market also saw substantial gains, with the Hang Seng Index rising over 2% and the Hang Seng Tech Index increasing over 3% [1] AI Industry - AI-related stocks surged, with notable gains including Guangku Technology and Robotech both hitting the 20% limit up, and Industrial Fulian also reaching the limit up [2][4] - Industrial Fulian reported a revenue of 360.76 billion yuan for the first half of 2025, a year-on-year increase of 35.58%, and a net profit of 12.11 billion yuan, up 38.61% [4][5] - The demand for AI servers is expected to grow significantly, driven by increased capital expenditures from major North American cloud service providers [4][5] Innovative Pharmaceuticals - The innovative drug sector saw strong performance, with Shouyao Holdings hitting the 20% limit up, and other companies like Microchip Biotech and WuXi AppTec also posting significant gains [6][8] - The National Medical Insurance Administration has established a "new drug pricing mechanism," which is expected to provide innovative drug manufacturers with greater pricing flexibility and efficiency [8] Humanoid Robotics - The humanoid robotics sector showed renewed activity, with companies like Shenglan Co. and Jieke Co. seeing substantial increases in stock prices [9][11] - The World Robot Conference held in Beijing highlighted advancements in embodied intelligent robots, with local governments offering subsidies for robot purchases [9][11] - The industry is expected to benefit from various supportive policies and events, including the upcoming World Humanoid Robot Games and other robotics-related conferences [11]

Market Overview - A-shares experienced a significant rally, with the Shanghai Composite Index achieving an 8-day winning streak and reaching a new high since December 2021, closing at 3683.46 points, up 0.48% [1] - The total trading volume in the A-share market exceeded 2 trillion yuan for the first time since February 27, indicating increased market activity [1] - The Hong Kong stock market also saw substantial gains, with the Hang Seng Index rising over 2% and the Hang Seng Tech Index increasing by more than 3% [1] AI Industry - Stocks in the AI industry chain surged, with notable gains including Guangku Technology and Robotech both hitting the 20% limit up, and Industrial Fulian also reaching the limit up [3][4] - Industrial Fulian reported a revenue of 360.76 billion yuan for the first half of 2025, a year-on-year increase of 35.58%, and a net profit of 12.113 billion yuan, up 38.61% [5] - The company attributed its growth to breakthroughs in AI technology and an expected increase in capital expenditure from major North American cloud service providers, which will drive demand for high-end AI servers [5][6] Innovative Drug Sector - The innovative drug sector saw strong performance, with Shouyao Holdings hitting the 20% limit up and other companies like Microchip Biotech and WuXi AppTec also experiencing significant gains [8][9] - The National Medical Insurance Administration has established a "new drug pricing mechanism," which is expected to provide innovative drug manufacturers with greater pricing flexibility and efficiency [10][11] Humanoid Robot Sector - The humanoid robot sector showed renewed activity, with companies like Shenglan Co. and Jieke Co. seeing substantial increases in stock prices, with several stocks hitting the limit up [13][14] - The World Robot Conference held in Beijing highlighted advancements in embodied intelligent robots, with local governments offering subsidies for robot purchases to stimulate the market [15]

创新药概念股，再度异动！ 在高位盘整多日之后，创新药概念股今日再度走强。临近午盘时分，首药控股直线拉升至20cm涨停，海思科盘中也触及涨停，药明康德、美迪西、常山 药业、凯莱英等纷纷走强。 从消息面来看，国家医保局12日对2025年国家医保药品目录初步形式审查结果进行公示，534个药品通过形式审查，较2024年明显增加。首次设立的商保 创新药目录共121个药品通过审查。有券商指出，在医保基础上补充发展商保，有利于具有创新性和临床价值的高价创新药落地。 创新药概念股拉升 8月13日，A股三大指数震荡攀升，创业板指大涨近3%。液冷服务器、CPO、PEEK材料、券商等板块纷纷走强。临近午盘时，创新药概念股也集体发力， 首药控股率先20cm涨停。紧随其后，海思科也被资金拉升至涨停板，股价创出历史新高。美迪西、上海谊众、仙琚制药、昭衍新药、常山药业、凯莱英 等纷纷跟涨。午后，行业巨头药明康德的股价涨幅一度超过8%，市值逼近2900亿元。 从消息面来看，创新药板块近期的利好消息相当密集。8月12日，国家医保局对2025年国家医保药品目录初步形式审查结果进行公示，534个药品通过形式 审查。 值得关注的是，2025年目录调 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年8月13日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 佔有關事件前的現有已發 | | 庫存股份變動 | 每股發行/出售價 (註4) ...

2025.08. 13 本文字数：957，阅读时长大约2分钟 作者 | 一财资讯 8月13日，沪指突破3674.4点，日线八连阳，创近4年新高。截至收盘，沪指涨0.48%，深成指涨 1.76%，创业板指涨3.62%。 | 代码 | 现价 涨跌 涨跌幅 | | --- | --- | | 000001 上证指数 | 3683.46c 17.55 0.48% | | 399001 深证成指 >> | 11551.36c 199.73 1.76% | | 899050 北证50 | 1461.86c 12.23 0.84% | | 881001 万得全A | 5801.59c 58.53 1.02% | | 000688 科别20 | 1077.70c 7.89 0.74% | | 399006 创业板指 | 2496.50c 87.11 3.62% | | 000300 沪深300 | 4176.58c 32.75 0.79% | 沪深两市全天成交额2.15万亿元，较昨日大幅放量。 个股涨多跌少，全市场超2700只个股上涨。 盘面上看，液冷服务器、工业金属、PEEK材料、CPO、光刻机等板块涨幅居前，煤炭、银行、 ...

Group 1: Market Performance - The three major indices showed strong performance, with the Shanghai Composite Index rising by 0.48%, surpassing last year's October high, while the Shenzhen Component Index increased by 1.76% and the ChiNext Index surged by 3.62% [1] - Over 2,600 stocks in the two markets experienced gains, with a total trading volume of approximately 2.15 trillion yuan [1] Group 2: Sector Highlights - The computing power, liquid cooling servers, and CPO concept stocks performed exceptionally well, with New Yisheng (300502.SZ) rising over 15%, and other notable gains from Zhongji Xuchuang (300308.SZ) at 11.66% and Cambridge Technology (603083.SH) at 9.93% [1] - PEEK materials saw collective strength, with companies like Huami New Materials (836247.BJ) and Xinhang New Materials (301076.SZ) experiencing significant increases [2] - The non-ferrous metals sector also performed well, with Electric Alloy (300697.SZ) rising over 9% and other companies like Luoyang Molybdenum (603993.SH) and Zhongfu Industrial (600595.SH) showing strong gains [2] Group 3: Economic Insights - Citic Securities noted that poor economic and employment data in the U.S. strengthened market expectations for a Federal Reserve rate cut in September, contributing to a broad rise in the non-ferrous metals sector [3] - The domestic push for "anti-involution" to optimize production factors is expected to enhance profitability across various sectors, benefiting metal prices [3] - The valuation of industrial metals is currently low, indicating potential for upward correction, with a bullish market for non-ferrous metals starting to emerge [3] Group 4: Policy and Market Sentiment - Dongguan Securities highlighted active market sentiment, suggesting an overweight position in the financial sector due to supportive policies aimed at enhancing the attractiveness of domestic capital markets [4] - The number of new A-share accounts opened in July reached 1.96 million, a significant year-on-year increase of 71%, indicating rising market participation and potential business opportunities for the securities industry [4] - Some sectors, including banks, coal, and logistics, experienced declines, with notable drops in stocks like Lu'an Huaneng (601699.SH) and Jiangsu Bank (600919.SH) [4]

此外，美国劳工统计局周二晚发布的数据显示，7月通胀表现相对平稳，分析人士称9月降息的障碍大大 降低，美联储或在下月重启降息。国信证券表示，投融资整体呈现回暖趋势。国内方面，临床前 CRO、临床CRO、CDMO业务价格止跌回稳，随着新签订单的稳步复苏，行业或将迎来反转；国际 CDMO业务方面，定价体系持续维持合理水平，疫情高基数影响已消化。 CRO概念股涨幅居前，截至发稿，维亚生物(01873)涨12.83%，报2.11港元；昭衍新药（603127） (06127)涨9.23%，报24.62港元；康龙化成（300759）(03759)涨7.27%，报22.12港元；药明康德 （603259）(02359)涨5.49%，报105.6港元；药明生物(02269)涨3.72%，报30.66港元。 消息面上，药明康德此前发布业绩并上调全年销售预期，公司上半年TIDES业务收入达到人民币50.3亿 元，同比增长141.6%，TIDES订单增长或与GLP-1领域需求高涨相关。中金公司（601995）认为，如今 创新药板块估值中枢上修，预期BD资金和二级热度上涨将反哺国内新药研发需求起量以及一级创新药 项目融资活跃度提升，内 ...

市场全天震荡走高，沪指突破去年10月8日高点，创近4年新高。截至收盘，沪指涨0.48%，深成指涨1.76%，创业板指涨3.62%。 盘面上，市场热点较为杂乱，个股涨多跌少，全市场超2700只个股上涨。 从板块来看，AI硬件股持续爆发，工业富联等多股续创历史新高。 券商股一度冲高，国盛金控2连板。 有色金属概念股震荡走强，紫金矿业、洛阳钼业双双创历史新高。 沪深两市成交额合计2.15万亿元，较上一交易日放量约2694.17亿元。其中，沪市成交额8870.23亿元，深市成交额1.26万亿元。 个股方面，东方财富成交额居首，为204亿元。其后是新易盛、中际旭创、寒武纪-U、宁德时代，成交额分别为135亿元、133亿元、114亿元、 107亿元。 | 序号 代码 名称 | | | | | | 【 ◎ 【 】 【 】 【 】 】 【 】 【 】 【 】 【 】 【 】 】 】 】 】 【 】 【 】 【 】 【 】 【 】 【 】 【 】 【 】 【 】 】 】 【 】 】 】 【 】 】 】 】 【 】 】 】 】 【 】 】 】 【 】 】 】 【 】 】 】 【 】 【 】 】 】 【 】 【 】 】 】 【 】 ...

Core Viewpoint - The innovative drug concept stocks have shown strong performance recently, driven by favorable policy developments and market dynamics [1][4][5]. Group 1: Market Performance - Innovative drug stocks surged, with Shouyao Holdings hitting a 20% limit up and Haishike also reaching the limit, alongside significant gains from companies like WuXi AppTec and MediSino [1][5]. - Since the start of the current market rally on April 8, the innovative drug sector has seen an overall increase of nearly 60%, with individual stocks like Shutai Shen rising nearly 7 times and Guangsheng Tang over 4 times [5][6]. Group 2: Policy Developments - The National Medical Insurance Administration (NMI) announced that 534 drugs passed the preliminary review for the 2025 National Medical Insurance Drug List, a significant increase from 2024 [4][6]. - A new commercial insurance innovative drug list was established, with 121 drugs approved, indicating a shift towards integrating commercial health insurance with basic medical insurance [6][7]. - The NMI's recent meetings emphasized support for genuine innovation in the pharmaceutical sector, aiming to enhance the quality of drugs and medical devices while rejecting subpar innovations [7][8]. Group 3: Industry Outlook - Analysts are optimistic about the investment opportunities within the pharmaceutical industry, driven by supportive policies and the potential for market recovery in the second half of 2025 [8][9]. - The total market size for innovative drugs in China is estimated to be between 200 billion and 300 billion, with significant growth potential as the country becomes a global R&D hub for innovative drugs [9]. - The policy environment remains favorable for innovative drugs, with major pharmaceutical companies gradually clearing risks associated with drug procurement, paving the way for competitive innovative drug pipelines [9].